The Application of Clinical Genetics Dovepress Inherited and Acquired Alterations in Development of Breast Cancer
暂无分享,去创建一个
[1] C. Atalay. Epigenetics in breast cancer. , 2013, Experimental oncology.
[2] R. Saxena,et al. ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective , 2012, Medicinal research reviews.
[3] H. Meijers-Heijboer,et al. PALB2 analysis in BRCA2-like families , 2011, Breast Cancer Research and Treatment.
[4] C. Croce,et al. MicroRNAs as therapeutic targets in cancer. , 2011, Translational research : the journal of laboratory and clinical medicine.
[5] S. Bianchi,et al. Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy , 2011, Breast Cancer Research and Treatment.
[6] S. Neuhausen,et al. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States , 2011, Breast Cancer Research and Treatment.
[7] D. Palli,et al. Mutation screening of RAD51C in male breast cancer patients , 2011, Breast Cancer Research.
[8] Andreas Rimner,et al. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. , 2011, Genes & development.
[9] E. John,et al. Germline mutations in PALB2 in African-American breast cancer cases , 2011, Breast Cancer Research and Treatment.
[10] J. Dopazo,et al. Exploring the Link between Germline and Somatic Genetic Alterations in Breast Carcinogenesis , 2010, PloS one.
[11] Jonathan W. Pillow,et al. POSTER PRESENTATION Open Access , 2013 .
[12] L. Ottini,et al. HER2-positive male breast cancer: an update. , 2010, Breast cancer.
[13] P. Watson,et al. Alternative Splicing in Prostate and Breast Cancer , 2010 .
[14] E. Sensi,et al. PALB2: a novel inactivating mutation in a Italian breast cancer family , 2010, Familial Cancer.
[15] M. Nóbrega,et al. An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. , 2010, Genome research.
[16] Marc Tischkowitz,et al. RAD51C germline mutations in breast and ovarian cancer patients , 2010, Breast Cancer Research.
[17] Jing Zhang,et al. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer , 2010, Breast Cancer Research and Treatment.
[18] Deborah Hughes,et al. Genome-wide association study identifies five new breast cancer susceptibility loci , 2010, Nature Genetics.
[19] F. Sera,et al. A PALB2 germline mutation associated with hereditary breast cancer in Italy , 2010, Familial Cancer.
[20] Dieter Niederacher,et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene , 2010, Nature Genetics.
[21] Olivia Fletcher,et al. Architecture of inherited susceptibility to common cancer , 2010, Nature Reviews Cancer.
[22] E. Levy-Lahad,et al. Fanconi anemia and breast cancer susceptibility meet again , 2010, Nature Genetics.
[23] Daniel J. Park,et al. Are PALB2 mutations associated with increased risk of male breast cancer? , 2010, Breast Cancer Research and Treatment.
[24] M. Troxell,et al. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma , 2010, Breast Cancer Research and Treatment.
[25] Thomas Streichert,et al. Identification of differentially expressed microRNAs in human male breast cancer , 2010, BMC Cancer.
[26] S. Bianchi,et al. PALB2 mutations in male breast cancer: a population-based study in Central Italy , 2010, Breast Cancer Research and Treatment.
[27] Lei Yao,et al. BRCA2 N372H polymorphism and breast cancer susceptibility: a meta-analysis involving 44,903 subjects , 2010, Breast Cancer Research and Treatment.
[28] M. Dąbrowska,et al. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients , 2010, BMC Medical Genetics.
[29] A. Levine,et al. Germline Mutations and Polymorphisms in the Origins of Cancers in Women , 2010, Journal of oncology.
[30] A. Børresen-Dale,et al. COMPLEX LANDSCAPES OF SOMATIC REARRANGEMENT IN HUMAN BREAST CANCER GENOMES , 2009, Nature.
[31] Philip S Rosenberg,et al. Male breast cancer: a population-based comparison with female breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] S. Shenouda,et al. MicroRNA function in cancer: oncogene or a tumor suppressor? , 2009, Cancer and Metastasis Reviews.
[33] D. Bell. Our changing view of the genomic landscape of cancer , 2009, The Journal of pathology.
[34] C. Croce. Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.
[35] F. Sera,et al. Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy , 2009, Breast Cancer Research and Treatment.
[36] Stefano Volinia,et al. MicroRNA expression profiling of male breast cancer , 2009, Breast Cancer Research.
[37] F. Sera,et al. BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy , 2009, Breast Cancer Research and Treatment.
[38] N. Guo,et al. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. , 2009, Cancer treatment reviews.
[39] A. Toland,et al. Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. , 2009, Seminars in cancer biology.
[40] W. Willett,et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1) , 2009, Nature Genetics.
[41] H. Nevanlinna,et al. The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype , 2009, Clinical Cancer Research.
[42] Z. Shao,et al. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives , 2009, Breast Cancer Research and Treatment.
[43] Anders Albrechtsen,et al. Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families , 2009, Breast Cancer Research and Treatment.
[44] P. Nederlof,et al. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. , 2009, Cancer research.
[45] S. Michiels,et al. Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. , 2009, The Lancet. Oncology.
[46] Z. Shao,et al. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives , 2009, Breast Cancer Research and Treatment.
[47] E. V. Rensburg,et al. PALB2 sequence variants in young South African breast cancer patients , 2009, Familial Cancer.
[48] Julian Peto,et al. Association of ESR1 gene tagging SNPs with breast cancer risk. , 2009, Human molecular genetics.
[49] J. Lubiński,et al. Genetic heterogeneity of 8q24 region in susceptibility to cancer. , 2009, Journal of the National Cancer Institute.
[50] M. Urioste,et al. Analysis of FANCB and FANCN/PALB2 Fanconi Anemia genes in BRCA1/2-negative Spanish breast cancer families , 2009, Breast Cancer Research and Treatment.
[51] S. Chanock,et al. Genetic Susceptibility Loci for Breast Cancer by Estrogen Receptor Status , 2008, Clinical Cancer Research.
[52] A. Jakubowska,et al. A range of cancers is associated with the rs6983267 marker on chromosome 8. , 2008, Cancer research.
[53] Yong-Yeon Cho,et al. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells , 2008, Breast Cancer Research.
[54] Sherif Abou Elela,et al. Identification of alternative splicing markers for breast cancer. , 2008, Cancer research.
[55] Qiong Shao,et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. , 2008, RNA.
[56] H. Sasaki,et al. Bmc Cancer , 2008 .
[57] Olufunmilayo I Olopade,et al. MYC in breast tumor progression , 2008, Expert review of anticancer therapy.
[58] J. Reis-Filho,et al. Hereditary breast cancer: from molecular pathology to tailored therapies , 2008, Journal of Clinical Pathology.
[59] John L Hopper,et al. Multiple loci with different cancer specificities within the 8q24 gene desert. , 2008, Journal of the National Cancer Institute.
[60] D. Palli,et al. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases , 2008, Breast Cancer Research and Treatment.
[61] A. Sigurdsson,et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer , 2008, Nature Genetics.
[62] Masaru Shinozaki,et al. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors , 2008, Breast Cancer Research.
[63] J. Bartlett,et al. Genetic alterations of CCND1 and EMSY in breast cancers , 2008, Histopathology.
[64] J. Simard,et al. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families , 2008, Journal of Human Genetics.
[65] Dieter Niederacher,et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. , 2008, American journal of human genetics.
[66] Z. Kolár̂,et al. The status and role of ErbB receptors in human cancer. , 2008, Experimental and molecular pathology.
[67] D. Coradini,et al. PIK3CA cancer mutations display gender and tissue specificity patterns , 2008, Human mutation.
[68] S. Bojesen,et al. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] Asli Silahtaroglu,et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. , 2007, Cancer research.
[70] W. Foulkes,et al. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women , 2007, Breast Cancer Research.
[71] P. Willems. Susceptibility genes in breast cancer: more is less? , 2007 .
[72] A. Sparks,et al. The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.
[73] C. de Wolf‐Peeters,et al. The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity , 2007, Current opinion in oncology.
[74] Xin Hu,et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers , 2007, Breast Cancer Research.
[75] D. Gudbjartsson,et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor–positive breast cancer , 2007, Nature Genetics.
[76] Lester L. Peters,et al. Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.
[77] Hongjuan Zhao,et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer , 2007, Breast Cancer Research.
[78] G. Sauter,et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer , 2007, Nature Genetics.
[79] M. Tejada,et al. Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer , 2007, Breast Cancer Research and Treatment.
[80] M. Tejada,et al. CHEK2 1100delC is present in familial breast cancer cases of the Basque Country , 2007, Breast Cancer Research and Treatment.
[81] Petra M. Nederlof,et al. Analysis of PALB2/FANCN-associated breast cancer families , 2007, Proceedings of the National Academy of Sciences.
[82] M. Esteller. Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.
[83] Katri Pylkäs,et al. A recurrent mutation in PALB2 in Finnish cancer families , 2007, Nature.
[84] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[85] Jaana M. Hartikainen,et al. A common coding variant in CASP8 is associated with breast cancer risk , 2007, Nature Genetics.
[86] S. Seal,et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.
[87] A. Ghaderi,et al. Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. , 2007, Cancer genetics and cytogenetics.
[88] M. Monden,et al. Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women , 2007, Clinical Cancer Research.
[89] A. Thompson,et al. Cyclin D1 and breast cancer. , 2006, Breast.
[90] Nazneen Rahman,et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.
[91] J. Soares,et al. Evaluation of ERBB2 Gene Status and Chromosome 17 Anomalies in Male Breast Cancer , 2006, The American journal of surgical pathology.
[92] G. Francis,et al. Evaluation of oestrogen and progesterone receptor status in HER‐2 positive breast carcinomas and correlation with outcome , 2006, Pathology.
[93] Nazneen Rahman,et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.
[94] B. Iacopetta,et al. DNA hypermethylation in breast cancer and its association with clinicopathological features. , 2006, Cancer letters.
[95] K. Edmiston,et al. HER-2 Status in Breast Cancer: Correlation of Gene Amplification by FISH With Immunohistochemistry Expression Using Advanced Cellular Imaging System , 2006, Applied immunohistochemistry & molecular morphology : AIMM.
[96] T. Walsh,et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. , 2006, JAMA.
[97] M. Murphy,et al. Polymorphisms in the p53 pathway , 2006, Oncogene.
[98] M. Urioste,et al. A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers , 2006, Human mutation.
[99] M. Campiglio,et al. Role of exon-16-deleted HER2 in breast carcinomas. , 2006, Endocrine-related cancer.
[100] B. Iacopetta,et al. PIK3CA mutations in breast cancer are associated with poor outcome , 2006, Breast Cancer Research and Treatment.
[101] Leif E. Peterson,et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[102] A. Marchetti,et al. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma , 2006, The Journal of pathology.
[103] S. Narod,et al. CHEK2 mutation and hereditary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[104] Li Zhao,et al. Oncogenic PI3K deregulates transcription and translation , 2005, Nature Reviews Cancer.
[105] A. Spurdle,et al. Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer , 2005, Breast Cancer Research.
[106] T. Dörk,et al. Association of two mutations in the CHEK2 gene with breast cancer , 2005, International journal of cancer.
[107] C. Croce,et al. MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.
[108] Lesley McGuffog,et al. Cancer risks and mortality in heterozygous ATM mutation carriers. , 2005, Journal of the National Cancer Institute.
[109] J. Kirk,et al. Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families , 2005, Journal of Medical Genetics.
[110] Hanina Hibshoosh,et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.
[111] Peter Schraml,et al. Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer , 2004, Cancer Research.
[112] P. Chappuis,et al. Significant Contribution of Germline BRCA2 Rearrangements in Male Breast Cancer Families , 2004, Cancer Research.
[113] Wayne A. Phillips,et al. Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.
[114] A. Auvinen,et al. Frequent amplification and overexpression of CCND1 in male breast cancer , 2004, International journal of cancer.
[115] J. Herman,et al. Hypermethylation in Histologically Distinct Classes of Breast Cancer , 2004, Clinical Cancer Research.
[116] Luke Hughes-Davies,et al. Amplification of the BRCA2 Pathway Gene EMSY in Sporadic Breast Cancer Is Related to Negative Outcome , 2004, Clinical Cancer Research.
[117] D. Seripa,et al. Nonrandom Distribution of Aberrant Promoter Methylation of Cancer-Related Genes in Sporadic Breast Tumors , 2004, Clinical Cancer Research.
[118] Douglas Easton,et al. The Genetic Epidemiology of Breast Cancer Genes , 2004, Journal of Mammary Gland Biology and Neoplasia.
[119] P. Radice,et al. The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy , 2004, Human mutation.
[120] Martin Widschwendter,et al. Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to Tamoxifen , 2004, Cancer Research.
[121] Hiroyuki Konishi,et al. The PIK3CA gene is mutated with high frequency in human breast cancers , 2004, Cancer biology & therapy.
[122] A. Auvinen,et al. CHEK2 1100delC is not a risk factor for male breast cancer population , 2004, International journal of cancer.
[123] E. Friedman,et al. CHEK2*1100delC and male breast cancer risk in Israel , 2004, International journal of cancer.
[124] D. Easton,et al. Role of CHEK2*1100delC in unselected series of non‐BRCA1/2 male breast cancers , 2004, International journal of cancer.
[125] M. Fackler,et al. DNA methylation of RASSF1A, HIN‐1, RAR‐β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma , 2003, International journal of cancer.
[126] E. Oláh,et al. Emerging roles of BRCA1 alternative splicing , 2003, Molecular pathology : MP.
[127] R. Wooster,et al. Breast and ovarian cancer. , 2003, The New England journal of medicine.
[128] J. Hopper,et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.
[129] T. Rebbeck,et al. Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1? , 2003, Journal of Medical Genetics.
[130] R. Winqvist,et al. No evidence of involvement of germline BACH1 mutations in Finnish breast and ovarian cancer families. , 2003, European journal of cancer.
[131] S. Narod,et al. A low frequency of non‐founder BRCA1 mutations in Ashkenazi Jewish breast–ovarian cancer families , 2002, Human mutation.
[132] R. Lidereau,et al. Molecular alterations in sporadic breast cancer. , 2002, Critical reviews in oncology/hematology.
[133] Nazneen Rahman,et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.
[134] D. Easton,et al. Variation in BRCA1 cancer risks by mutation position. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[135] B. Ward,et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[136] Douglas F. Easton,et al. Polygenic susceptibility to breast cancer and implications for prevention , 2002, Nature Genetics.
[137] R. Delongchamp,et al. Prospects for applying genotypic selection of somatic oncomutation to chemical risk assessment. , 2001, Mutation research.
[138] M. Olivier,et al. TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. , 2001, Seminars in cancer biology.
[139] P. Radice,et al. Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer , 2001, Human mutation.
[140] L. Kadouri,et al. A deletion/insertion mutation in the BRCA2 gene in a breast cancer family: A possible role of the Alu‐polyA tail in the evolution of the deletion , 2001, Genes, chromosomes & cancer.
[141] S. Seal,et al. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[142] J. Kononen,et al. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. , 2000, Cancer research.
[143] B. Weber,et al. Genetic and hormonal risk factors in breast cancer. , 2000, Journal of the National Cancer Institute.
[144] J. Ross,et al. The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, The oncologist.
[145] M. Hung,et al. A novel splice variant of HER2 with increased transformation activity , 1998, Molecular carcinogenesis.
[146] J Chang-Claude,et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.
[147] D. Clayton,et al. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. , 1997, Human molecular genetics.
[148] M. Skolnick,et al. BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations. , 1996, Oncogene.
[149] R. Zeillinger,et al. Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors , 1996, International journal of cancer.
[150] D. Easton,et al. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. , 1996, Cancer research.
[151] M. Skolnick,et al. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. , 1996, Human molecular genetics.
[152] J. Eyfjörd,et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes , 1996, Nature Genetics.
[153] S. Weitzman,et al. Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[154] J. Gudmundsson,et al. Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. , 1996, American journal of human genetics.
[155] F. Collins,et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals , 1995, Nature Genetics.
[156] S. Friend,et al. Screening for germ line TP53 mutations in breast cancer patients. , 1992, Cancer research.
[157] C. Harris,et al. Oncogenes and tumor-suppressor genes. , 1991, Environmental health perspectives.
[158] M. Swift,et al. Breast and other cancers in families with ataxia-telangiectasia. , 1987, The New England journal of medicine.
[159] S. Tommasi,et al. Gene copy number variation in male breast cancer by aCGH , 2011, Cellular Oncology.
[160] E. V. Rensburg,et al. Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation , 2010, Breast Cancer Research and Treatment.
[161] A. Russo,et al. Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation? , 2008, Breast Cancer Research and Treatment.
[162] Georgia Chenevix-Trench,et al. Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors , 2008, Breast Cancer Research and Treatment.
[163] F. Liebens,et al. Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. , 2007, European journal of cancer.
[164] Nazneen Rahman,et al. The emerging landscape of breast cancer susceptibility , 2007, Nature Genetics.
[165] A. Kallioniemi,et al. Large genomic BRCA2 rearrangements and male breast cancer. , 2006, Cancer detection and prevention.
[166] A. P. Damin,et al. Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. , 2006, Cancer detection and prevention.
[167] Shih-Feng Tsai,et al. Chromosomal comparative genomic hybridization abnormalities in early- and late-onset human breast cancers: correlation with disease progression and TP53 mutations. , 2004, Cancer genetics and cytogenetics.
[168] S. Tsutsui,et al. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer , 2004, Breast Cancer Research and Treatment.
[169] K. Shiraki,et al. Breast cancer genetics: what we know and what we need , 2001, Nature Medicine.
[170] A. Lindblom,et al. A study of the PTEN/MMAC1 gene in 136 breast cancer families. , 1998, Human genetics.
[171] R. Tuckuviene,et al. submit your manuscript | www.dovepress.com , 2022 .